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Abstract
Background: Syphilis has been associated with an increase in HIV RNA and a temporary decline in CD4 T cell
counts in people living with HIV who are not receiving antiretroviral treatment (ART), and may be associated with a
transient HIV RNA rebound in those who are receiving ART. Our case is the first to highlight the risk of a multidrug-
resistant HIV viral rebound during the course of early syphilis even if antiretroviral drug concentrations are within
the therapeutic range.
Case presentation: This 50-year-old HIV-1-positive male patient with concomitant early syphilis presented with an HIV
RNA rebound (8908 copies/mL) during a scheduled visit to our clinic. He was receiving a stable ART regimen consisting
of darunavir/cobicistat plus dolutegravir, and had a 15-year history of viral suppression. Good short-term drug
adherence could be inferred as liquid chromatography tandem mass spectrometry showed that his trough
antiretroviral drug concentrations were within the therapeutic range: darunavir 2353 ng/mL (minimum effective
concentration > 500 ng/mL) and dolutegravir 986 ng/mL (minimum effective concentration > 100 ng/mL). A plasma
RNA genotype resistance test revealed wild-type virus in the integrase region and protease region (PR), but extensive
resistance in the reverse transcriptase (RT) region (M41L, E44D, D67N, K70R, M184V, L210W and T215Y). Phylogenetic
analysis of next-generation sequences (used to investigate the presence of minor viral variants), the PR and RT
sequences from plasma HIV RNA and pro-viral DNA extracted from peripheral blood mononuclear cells during the viral
rebound, and a Sanger sequence obtained during a previous virological failure suggested clonal viral expression
because the previous PR resistance mutations had been lost or had not been archived in pro-viral DNA.
Conclusions: This case shows that early syphilis may cause an HIV RNA rebound in patients under stable virological
control with the potential of transmitting an extensively drug-resistant virus.
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Background
There has recently been an increase in the incidence of
sexually transmitted diseases (STDs) among men who
have sex with men (MSM), whether they are people liv-
ing with HIV/AIDS (PLWHAs) or the recipients of pre-
exposure prophylaxis (PrEP) [1, 2]. Syphilis is an STD
that has been associated with an increase in HIV RNA
and a temporary decline in cluster of differentiation
(CD) 4 T cell counts in patients not receiving antiretro-
viral treatment (ART) [3], and concomitant early syphilis
has been associated with a transient rebound in HIV
viral load in PLWHAs receiving effective ART [4].
We here describe the case of an HIV-infected MSM
with early syphilis experiencing a viral rebound and
showing extensive resistance in the reverse transcriptase
(RT) region. This is the first case to highlight the risk of
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an HIV multidrug-resistant viral rebound during early
syphilis even when antiretroviral drug concentrations are
within the therapeutic range.
Case presentation
During a scheduled visit in September 2018, a 50-year-
old MSM with early syphilis infection, who had tested
positive for clade B HIV-1 in December 1991 and had
subsequently been regularly followed up at our centre,
was found to be affected by an HIV RNA rebound (8908
copies/mL). Figure 1 shows the patient’s medical history:
he started ART in December 1993 with a CD4 T cell
nadir of 97 cells/μL and an HIV RNA zenith of 98,000
copies/mL. It is worth noting that he initially received
sub-optimal ART based on a combination of thymidine
analogues, nucleoside RT inhibitors, and the first prote-
ase (PR) inhibitors that led to multiple virological fail-
ures (VFs). A genotype resistance test (GRT) in June
2002 (Trugene® HIV-1 Genotyping Assay, Siemens
Healthcare Diagnostics GmbH, Eschborn, Germany)
showed extensive resistance in the RT region (M41L,
E44D, D67N, V118L, M184V, L210W, and T215Y) and
the PR region (L10I, M46L, L63P, V82T, and L90M),
and a tropism test in 2013 (envelope glycoprotein
(gp)120 V3 loop sequencing) revealed a C-C chemokine
receptor type 5 (CCR5) tropic virus with a false positive
rate of 91.3% (geno2pheno co-receptor tool). However,
the patient had experienced stable virological suppres-
sion from 2003, when he started an ART regimen based
on tenofovir disoproxil fumarate (TDF), efavirenz (EFV),
and lopinavir/ritonavir (LPV/r), which was simplified to
darunavir/ritonavir (DRV/r) and dolutegravir (DTG) in
April 2015, and further simplified to DRV/cobicistat
(DRV/c) and DTG in April 2016.
At the time of the viral rebound, the patient’s syphilis
was considered to be in an early stage as a rapid plasma
reagin (RPR) test within 12months of the index event
was negative after treatment with benzathine penicillin
for primary syphilis infection (RPR titre down from 1:32
to < 1:1 in March 2015), but the titre had increased to 1:
4 in December 2017. Moreover, the patient reported that
he had had multiple condomless, insertive/receptive anal
intercourses in the previous months.
After being purified by means of solid-phase extraction,
the plasma sample used to quantify his HIV RNA viral
load (handled on ice and stored at − 20 °C) was used to
determine trough antiretroviral drug concentrations by
means of liquid chromatography tandem mass spectrom-
etry. The results indicated good short-term adherence to
the prescribed ART as the trough concentrations were
Fig. 1 The patient’s medical history. The continuous red line represents the trend of HIV RNA levels over time, and the dashed red line represents
the threshold of HIV RNA levels of < 50 copies/μL. The boxes contain brief descriptions of major clinical events. A schematic representation of the
patient’s history of ART is given below the graph. Abbreviations: cp: copies; ART: antiretroviral treatment; VF: virological failure; RPR: rapid plasma
reagin; FPR: false positive rate; RT: reverse transcriptase; PR: protease; NRTIs: nucleoside reverse transcriptase inhibitors; RTV: ritonavir; IDV: indinavir;
NFV: nelfinavir; TDF: tenofovir; EFV: efavirenz; LPV/r: lopinavir/ritonavir; DTG: dolutegravir; DRV/r: darunavir/ritonavir; DRV/c: darunavir/cobicistat
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within the therapeutic range (DRV 2353 ng/mL, minimum
effective concentration > 500 ng/mL; DTG 986 ng/mL,
minimum effective concentration > 100 ng/mL). Further-
more, all of the previous assessments of the trough con-
centrations of both drugs (carried out at least twice a year
in our clinical practice) had always shown levels within
the therapeutic range, which provides indirect evidence of
long-term treatment compliance.
Viral rebound was assessed by means of genotype re-
sistance tests (GRTs, Viroseq HIV-1 Genotyping System
v. 2, ViroSeq; Abbott GmbH, Wiesbaden, Germany).
The test of plasma RNA showed wild-type virus in the
PR and integrase region, but extensive resistances in the
RT region (M41L, E44D, D67N, K70R, M184V, L210W
and T215Y), and the test of plasma DNA showed the
same resistance profile. In order to investigate the pres-
ence of minor viral variants, next-generation sequencing
analysis (NGS) of the same samples (NGS HIV-1
Solution kit, Arrow Diagnostics S.r.l., Genova, Italy) re-
vealed the presence of PR variants in < 1.0% of the viral
population in the plasma RNA sample (DNA data are
not available because of a failure in the amplification
process). Phylogenetic analyses of Sanger PR and RT se-
quences obtained from plasma HIV RNA and pro-viral
DNA extracted from peripheral blood mononuclear cells
during the viral rebound, and a sequence obtained from
the same patient during a previous VF in 2002 revealed
close correlations, especially between the RNA and DNA
samples simultaneously collected in 2018 (Fig. 2). These
findings suggested clonal viral expression as previous PR
resistance mutations had been lost or not archived in
the pro-viral DNA.
Four weeks after the viral rebound, the patient was still
on the same ART with undetectable HIV RNA and, 3
months after treatment with benzathine penicillin, the
RPR titre was 1:1.
Discussion and conclusions
The finding that there is no viral transmission between
sero-different couples when the HIV-positive partner has
Fig. 2 Phylogenetic tree showing the relationships between the three PR and RT Sanger sequences collected from the patient during virological
failure in June 2003 (HIV RNA) and during the virological rebound concomitant with early syphilis in September 2018 (HIV RNA and HIV DNA)
Giacomelli et al. BMC Infectious Diseases          (2020) 20:273 Page 3 of 5
HIV RNA levels below the threshold of 200 copies/mL [5]
has led to the undetectable = untransmittable (U=U) cam-
paign [6], which has reduced the stigma associated with
HIV infection and promoted the retention in care of
PLWHAs [7]. It is also well known that factors such as
bacterial infections, influenza vaccinations and poor ad-
herence to ART can cause a transient viral rebound that
may not require a change in antiretroviral regimen: inter-
estingly, Kolber et al. found that seven of their 34 patients
experienced a viral rebound after an influenza vaccination,
two of whom showed RT and PR mutations [8–11], al-
though it is not clear whether these were primary muta-
tions or a spillover of previous archived mutations [10].
It has been reported that the incidence of syphilis (like
that of other STDs) is increasing among MSM world-
wide [1, 2], and a number of authors have postulated
that early syphilis increases HIV viremia and reduces
CD4 T cell counts [3, 4]. The first study of a mixed pop-
ulations of patients with uncontrolled HIV viremia and
patients receiving ART found that the patients with HIV
RNA levels of < 500 copies/mL and early syphilis experi-
enced an increased viral load during the first 6 months
after the presumed date of infection: 27% of the patients
with early syphilis showed an increase in HIV RNA to
between 1392 and 10,500 copies/mL, with a median dur-
ation of detectable viremia of 1.6 months (interquartile
range: 1.6–7.3), and the authors suggested that early
syphilis increased the risk of HIV transmission even in
patients with HIV RNA levels of < 500 copies/mL [4].
Conversely, Grewal et al. did not observe an increased
risk of VF in a Canadian cohort of PLWHA MSM with
acute syphilis who were receiving effective ART: the
overall incidence of VF was 3.5/100 person-years (95%
confidence interval: 3.4–4.2) and, as there was no statis-
tically significant association with acute syphilis, the au-
thors concluded that ART may still reduce the risk of
transmitting HIV to sexual partners [12]. However, this
conclusion is undermined by the fact that it is question-
able whether syphilis causes VF or simply a temporary
loss of virological control that can often be regained
without changing ART. Secondly, the short duration of
detectable HIV viremia following an episode of early
syphilis in patients under virological control [4] suggests
that a virological rebound may be limited between two
consecutive HIV RNA determinations.
Our phylogenetic analysis reasonably excluded the
possibility that the mutations observed during our pa-
tient’s viral rebound were due to HIV super-infection
[13, 14], but the rebound may have been due to previ-
ously archived viruses. Interestingly, the RT mutations
were similar to those found during a previous VF, but
the previously detected PR mutations were not identi-
fied. This may be partially explained by the different dy-
namics of HIV resistance mutations in the absence of
antiretroviral pressure: the loss of RT mutations is
slower than the loss of PR mutations [15].
At the time of the viral rebound, our patent had
trough concentrations of antiretrovirals within the thera-
peutic range. As therapeutic drug monitoring (TDM)
can only provide evidence of short-term compliance to
treatment, we cannot exclude the possibility that he may
not have been compliant in the weeks before the event.
However, he was regularly followed up at our clinic and
all of the previous TDM assessments (made at least
twice a year) also showed therapeutic drug concentra-
tions, thus indirectly suggesting long-term adherence.
Our case suggests that early syphilis can cause an al-
beit time-limited rebound of HIV viremia in patients
with self reported good adherence to ART and antiretro-
viral trough concentrations within the therapeutic range.
The HIV RNA levels reached during the rebound are
consistent with a high rate of HIV transmission [16],
and the highly resistant nature of the detected virus is
worth noting because of the potential risk of transmit-
ting a drug-resistant virus. The vigilant monitoring of
STDs, particularly syphilis, in such a high-risk popula-
tion is necessary in order to be able to ensure an early
diagnosis and prompt treatment.
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